Rossari Biotech · NSE: ROSSARI · BSE: 543213
Q3 FY21 results · Oct–Dec 2020
Rossari Biotech reported revenue from operations of ₹209.98 crore and net profit of ₹21.62 crore for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 209.98 | — | — | 171.67 | +22.3% |
| Other income | 0.76 | — | — | 3.95 | −80.8% |
| Total income | 210.74 | — | — | 175.62 | +20.0% |
| Profit before tax | 28.38 | — | — | 27.76 | +2.2% |
| Net profit for the period | 21.62 | — | — | 20.73 | +4.3% |
| Attributable to shareholders of the company | 21.60 | — | — | 20.70 | +4.4% |
| EPS, basic (₹) | 4.16 | — | — | 4.07 | +2.2% |
| Net margin (%) | 10.3 | — | 12.1 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 205.76 | — | — | 173.71 | +18.4% |
| Other income | 1.10 | — | — | 4.99 | −77.9% |
| Total income | 206.86 | — | — | 178.69 | +15.8% |
| Profit before tax | 27.29 | — | — | 28.88 | −5.5% |
| Net profit for the period | 20.64 | — | — | 21.79 | −5.2% |
| EPS, basic (₹) | 3.98 | — | — | 4.27 | −6.8% |
| Net margin (%) | 10.0 | — | 12.5 |
Consolidated
- Filed with BSE
- 23 Jan 2021, 16:51 IST
- Board meeting
- 23 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 Jan 2021, 16:51 IST
- Board meeting
- 23 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE